Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 583 entries
Sorted by: Best Match Show Resources per page
In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii.

Revista iberoamericana de micologia

De Bedout C, Ordóñez N, Gómez BL, Rodríguez MC, Arango M, Restrepo A, Castañeda E.
PMID: 18473590
Rev Iberoam Micol. 1999 Mar;16(1):36-9.

One of the differences observed between the two varieties of Cryptococcus neoformansis the greater difficulty to achieve an adequate therapeutical response in patients affected by C. neoformans var. gattii, an observation that has been validated in vitro only rarely....

Cite
De Bedout C, Ordóñez N, Gómez BL, et al. In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii. Rev Iberoam Micol. 1999;16(1):36-9
De Bedout, C., Ordóñez, N., Gómez, B. L., Rodríguez, M. C., Arango, M., Restrepo, A., & Castañeda, E. (1999). In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii. Revista iberoamericana de micologia, 16(1), 36-9.
De Bedout, C, et al. "In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii." Revista iberoamericana de micologia vol. 16,1 (1999): 36-9.
De Bedout C, Ordóñez N, Gómez BL, Rodríguez MC, Arango M, Restrepo A, Castañeda E. In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii. Rev Iberoam Micol. 1999 Mar;16(1):36-9. PMID: 18473590.
Copy Download .nbib Format: NLM
Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates.

Antimicrobial agents and chemotherapy

Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, Tyson GH, Zhao S, Hsu CH, McDermott PF, Tadesse DA, Morales C, Simmons M, Tillman G, Wasilenko J, Folster JP, Klimke W.
PMID: 31427293
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.00483-19. Print 2019 Nov.

Antimicrobial resistance (AMR) is a major public health problem that requires publicly available tools for rapid analysis. To identify AMR genes in whole-genome sequences, the National Center for Biotechnology Information (NCBI) has produced AMRFinder, a tool that identifies AMR...

Cite
Feldgarden M, Brover V, Haft DH, et al. Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates. Antimicrob Agents Chemother. 2019;63(11)doi: 10.1128/AAC.00483-19.
Feldgarden, M., Brover, V., Haft, D. H., Prasad, A. B., Slotta, D. J., Tolstoy, I., Tyson, G. H., Zhao, S., Hsu, C. H., McDermott, P. F., Tadesse, D. A., Morales, C., Simmons, M., Tillman, G., Wasilenko, J., Folster, J. P., & Klimke, W. (2019). Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates. Antimicrobial agents and chemotherapy, 63(11), . https://doi.org/10.1128/AAC.00483-19
Feldgarden, Michael, et al. "Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates." Antimicrobial agents and chemotherapy vol. 63,11 (2019). doi: https://doi.org/10.1128/AAC.00483-19
Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, Tyson GH, Zhao S, Hsu CH, McDermott PF, Tadesse DA, Morales C, Simmons M, Tillman G, Wasilenko J, Folster JP, Klimke W. Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates. Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.00483-19. Print 2019 Nov. PMID: 31427293; PMCID: PMC6811410.
Copy Download .nbib Format: NLM
Erratum for Rutter et al., Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.

Antimicrobial agents and chemotherapy

Rutter WC, Cox JN, Martin CA, Burgess DR, Burgess DS.
PMID: 28341811
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.00314-17. Print 2017 Apr.

No abstract available.

Cite
Rutter WC, Cox JN, Martin CA, et al. Erratum for Rutter et al., Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime. Antimicrob Agents Chemother. 2017;61(4)doi: 10.1128/AAC.00314-17.
Rutter, W. C., Cox, J. N., Martin, C. A., Burgess, D. R., & Burgess, D. S. (2017). Erratum for Rutter et al., Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime. Antimicrobial agents and chemotherapy, 61(4), . https://doi.org/10.1128/AAC.00314-17
Rutter, W Cliff, et al. "Erratum for Rutter et al., Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime." Antimicrobial agents and chemotherapy vol. 61,4 (2017). doi: https://doi.org/10.1128/AAC.00314-17
Rutter WC, Cox JN, Martin CA, Burgess DR, Burgess DS. Erratum for Rutter et al., Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime. Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.00314-17. Print 2017 Apr. PMID: 28341811; PMCID: PMC5365690.
Copy Download .nbib Format: NLM
Correction for Tun-Yhong et al., "Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11".

Antimicrobial agents and chemotherapy

Tun-Yhong W, Chinpaisal C, Pamonsinlapatham P, Kaewkitichai S.
PMID: 28939584
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01753-17. Print 2017 Oct.

No abstract available.

Cite
Tun-Yhong W, Chinpaisal C, Pamonsinlapatham P, et al. Correction for Tun-Yhong et al., "Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11". Antimicrob Agents Chemother. 2017;61(10)doi: 10.1128/AAC.01753-17.
Tun-Yhong, W., Chinpaisal, C., Pamonsinlapatham, P., & Kaewkitichai, S. (2017). Correction for Tun-Yhong et al., "Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11". Antimicrobial agents and chemotherapy, 61(10), . https://doi.org/10.1128/AAC.01753-17
Tun-Yhong, Wisith, et al. "Correction for Tun-Yhong et al., "Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11"." Antimicrobial agents and chemotherapy vol. 61,10 (2017). doi: https://doi.org/10.1128/AAC.01753-17
Tun-Yhong W, Chinpaisal C, Pamonsinlapatham P, Kaewkitichai S. Correction for Tun-Yhong et al., "Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11". Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01753-17. Print 2017 Oct. PMID: 28939584; PMCID: PMC5610500.
Copy Download .nbib Format: NLM
Erratum for Fang et al., "High Genetic Plasticity in Multidrug-Resistant Sequence Type 3-IncHI2 Plasmids Revealed by Sequence Comparison and Phylogenetic Analysis".

Antimicrobial agents and chemotherapy

Fang LX, Li XP, Deng GH, Li SM, Yang RS, Wu ZW, Liao XP, Sun J, Liu YH.
PMID: 29700006
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.00579-18. Print 2018 May.

No abstract available.

Cite
Fang LX, Li XP, Deng GH, et al. Erratum for Fang et al., "High Genetic Plasticity in Multidrug-Resistant Sequence Type 3-IncHI2 Plasmids Revealed by Sequence Comparison and Phylogenetic Analysis". Antimicrob Agents Chemother. 2018;62(5)doi: 10.1128/AAC.00579-18.
Fang, L. X., Li, X. P., Deng, G. H., Li, S. M., Yang, R. S., Wu, Z. W., Liao, X. P., Sun, J., & Liu, Y. H. (2018). Erratum for Fang et al., "High Genetic Plasticity in Multidrug-Resistant Sequence Type 3-IncHI2 Plasmids Revealed by Sequence Comparison and Phylogenetic Analysis". Antimicrobial agents and chemotherapy, 62(5), . https://doi.org/10.1128/AAC.00579-18
Fang, Liang-Xing, et al. "Erratum for Fang et al., "High Genetic Plasticity in Multidrug-Resistant Sequence Type 3-IncHI2 Plasmids Revealed by Sequence Comparison and Phylogenetic Analysis"." Antimicrobial agents and chemotherapy vol. 62,5 (2018). doi: https://doi.org/10.1128/AAC.00579-18
Fang LX, Li XP, Deng GH, Li SM, Yang RS, Wu ZW, Liao XP, Sun J, Liu YH. Erratum for Fang et al., "High Genetic Plasticity in Multidrug-Resistant Sequence Type 3-IncHI2 Plasmids Revealed by Sequence Comparison and Phylogenetic Analysis". Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.00579-18. Print 2018 May. PMID: 29700006; PMCID: PMC5923164.
Copy Download .nbib Format: NLM
A practical thrice weekly ertapenem in hemodialysis patients.

Antimicrobial agents and chemotherapy

Ueng YF, Wang HJ, Wu SC, Ng YY.
PMID: 31527026
Antimicrob Agents Chemother. 2019 Sep 16; doi: 10.1128/AAC.01427-19. Epub 2019 Sep 16.

Change of ertapenem dosage from 500 mg daily to thrice weekly after each hemodialysis session can maintain the plasma concentration above 2 mg/L, and be practical in hemodialysis patients.

Cite
Ueng YF, Wang HJ, Wu SC, et al. A practical thrice weekly ertapenem in hemodialysis patients. Antimicrob Agents Chemother. 2019;doi: 10.1128/AAC.01427-19.
Ueng, Y. F., Wang, H. J., Wu, S. C., & Ng, Y. Y. (2019). A practical thrice weekly ertapenem in hemodialysis patients. Antimicrobial agents and chemotherapy, . https://doi.org/10.1128/AAC.01427-19
Ueng, Yune-Fang, et al. "A practical thrice weekly ertapenem in hemodialysis patients." Antimicrobial agents and chemotherapy vol. (2019). doi: https://doi.org/10.1128/AAC.01427-19
Ueng YF, Wang HJ, Wu SC, Ng YY. A practical thrice weekly ertapenem in hemodialysis patients. Antimicrob Agents Chemother. 2019 Sep 16; doi: 10.1128/AAC.01427-19. Epub 2019 Sep 16. PMID: 31527026; PMCID: PMC6879214.
Copy Download .nbib Format: NLM
Re-growth of .

Antimicrobial agents and chemotherapy

Hendon-Dunn CL, Pertinez H, Marriott AAN, Hatch K, Allnutt JC, Davies G, Bacon J.
PMID: 31527023
Antimicrob Agents Chemother. 2019 Sep 16; doi: 10.1128/AAC.00570-19. Epub 2019 Sep 16.

Modulation of growth rate in

Cite
Hendon-Dunn CL, Pertinez H, Marriott AAN, et al. Re-growth of . Antimicrob Agents Chemother. 2019;doi: 10.1128/AAC.00570-19.
Hendon-Dunn, C. L., Pertinez, H., Marriott, A. A. N., Hatch, K., Allnutt, J. C., Davies, G., & Bacon, J. (2019). Re-growth of . Antimicrobial agents and chemotherapy, . https://doi.org/10.1128/AAC.00570-19
Hendon-Dunn, Charlotte L, et al. "Re-growth of ." Antimicrobial agents and chemotherapy vol. (2019). doi: https://doi.org/10.1128/AAC.00570-19
Hendon-Dunn CL, Pertinez H, Marriott AAN, Hatch K, Allnutt JC, Davies G, Bacon J. Re-growth of . Antimicrob Agents Chemother. 2019 Sep 16; doi: 10.1128/AAC.00570-19. Epub 2019 Sep 16. PMID: 31527023; PMCID: PMC6879242.
Copy Download .nbib Format: NLM
A 2.5-years within-patient evolution of a .

Antimicrobial agents and chemotherapy

Boulant T, Jousset AB, Bonnin RA, Barrail-Tran A, Borgel A, Oueslati S, Naas T, Dortet L.
PMID: 31636072
Antimicrob Agents Chemother. 2019 Oct 21; doi: 10.1128/AAC.01637-19. Epub 2019 Oct 21.

Ceftolozane-tazobactam is considered to be a last resort treatment for infections caused by multidrug-resistant (MDR)

Cite
Boulant T, Jousset AB, Bonnin RA, et al. A 2.5-years within-patient evolution of a . Antimicrob Agents Chemother. 2019;doi: 10.1128/AAC.01637-19.
Boulant, T., Jousset, A. B., Bonnin, R. A., Barrail-Tran, A., Borgel, A., Oueslati, S., Naas, T., & Dortet, L. (2019). A 2.5-years within-patient evolution of a . Antimicrobial agents and chemotherapy, . https://doi.org/10.1128/AAC.01637-19
Boulant, Thibaud, et al. "A 2.5-years within-patient evolution of a ." Antimicrobial agents and chemotherapy vol. (2019). doi: https://doi.org/10.1128/AAC.01637-19
Boulant T, Jousset AB, Bonnin RA, Barrail-Tran A, Borgel A, Oueslati S, Naas T, Dortet L. A 2.5-years within-patient evolution of a . Antimicrob Agents Chemother. 2019 Oct 21; doi: 10.1128/AAC.01637-19. Epub 2019 Oct 21. PMID: 31636072; PMCID: PMC6879234.
Copy Download .nbib Format: NLM
Erratum for Choudhary et al., "Essential Role for the Phosphatidylinositol 3,5-Bisphosphate Synthesis Complex in Caspofungin Tolerance and Virulence in Candida glabrata".

Antimicrobial agents and chemotherapy

Choudhary DK, Bhakt P, Kaur R.
PMID: 31640980
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01794-19. Print 2019 Nov.

No abstract available.

Cite
Choudhary DK, Bhakt P, Kaur R. Erratum for Choudhary et al., "Essential Role for the Phosphatidylinositol 3,5-Bisphosphate Synthesis Complex in Caspofungin Tolerance and Virulence in Candida glabrata". Antimicrob Agents Chemother. 2019;63(11)doi: 10.1128/AAC.01794-19.
Choudhary, D. K., Bhakt, P., & Kaur, R. (2019). Erratum for Choudhary et al., "Essential Role for the Phosphatidylinositol 3,5-Bisphosphate Synthesis Complex in Caspofungin Tolerance and Virulence in Candida glabrata". Antimicrobial agents and chemotherapy, 63(11), . https://doi.org/10.1128/AAC.01794-19
Choudhary, Deepak Kumar, et al. "Erratum for Choudhary et al., "Essential Role for the Phosphatidylinositol 3,5-Bisphosphate Synthesis Complex in Caspofungin Tolerance and Virulence in Candida glabrata"." Antimicrobial agents and chemotherapy vol. 63,11 (2019). doi: https://doi.org/10.1128/AAC.01794-19
Choudhary DK, Bhakt P, Kaur R. Erratum for Choudhary et al., "Essential Role for the Phosphatidylinositol 3,5-Bisphosphate Synthesis Complex in Caspofungin Tolerance and Virulence in Candida glabrata". Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01794-19. Print 2019 Nov. PMID: 31640980; PMCID: PMC6811420.
Copy Download .nbib Format: NLM
Erratum for Kieffer et al., ".

Antimicrobial agents and chemotherapy

Kieffer N, Royer G, Decousser JW, Bourrel AS, Palmieri M, Ortiz De La Rosa JM, Jacquier H, Denamur E, Nordmann P, Poirel L.
PMID: 31640981
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01866-19. Print 2019 Nov.

No abstract available.

Cite
Kieffer N, Royer G, Decousser JW, et al. Erratum for Kieffer et al., ". Antimicrob Agents Chemother. 2019;63(11)doi: 10.1128/AAC.01866-19.
Kieffer, N., Royer, G., Decousser, J. W., Bourrel, A. S., Palmieri, M., Ortiz De La Rosa, J. M., Jacquier, H., Denamur, E., Nordmann, P., & Poirel, L. (2019). Erratum for Kieffer et al., ". Antimicrobial agents and chemotherapy, 63(11), . https://doi.org/10.1128/AAC.01866-19
Kieffer, Nicolas, et al. "Erratum for Kieffer et al., "." Antimicrobial agents and chemotherapy vol. 63,11 (2019). doi: https://doi.org/10.1128/AAC.01866-19
Kieffer N, Royer G, Decousser JW, Bourrel AS, Palmieri M, Ortiz De La Rosa JM, Jacquier H, Denamur E, Nordmann P, Poirel L. Erratum for Kieffer et al., ". Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01866-19. Print 2019 Nov. PMID: 31640981; PMCID: PMC6811415.
Copy Download .nbib Format: NLM
Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate.

Antimicrobial agents and chemotherapy

Greaves W, Wan H, Yee KL, Kandala B, Vaddady P, Hwang C.
PMID: 31548188
Antimicrob Agents Chemother. 2019 Sep 23; doi: 10.1128/AAC.01298-19. Epub 2019 Sep 23.

Doravirine is a non-nucleoside reverse transcriptase inhibitor approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after stopping efavirenz. In a post-hoc subgroup analysis of participants who...

Cite
Greaves W, Wan H, Yee KL, et al. Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate. Antimicrob Agents Chemother. 2019;doi: 10.1128/AAC.01298-19.
Greaves, W., Wan, H., Yee, K. L., Kandala, B., Vaddady, P., & Hwang, C. (2019). Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate. Antimicrobial agents and chemotherapy, . https://doi.org/10.1128/AAC.01298-19
Greaves, Wayne, et al. "Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate." Antimicrobial agents and chemotherapy vol. (2019). doi: https://doi.org/10.1128/AAC.01298-19
Greaves W, Wan H, Yee KL, Kandala B, Vaddady P, Hwang C. Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate. Antimicrob Agents Chemother. 2019 Sep 23; doi: 10.1128/AAC.01298-19. Epub 2019 Sep 23. PMID: 31548188; PMCID: PMC6879224.
Copy Download .nbib Format: NLM
Translation Elongation Factor 4 (LepA) Contributes to Tetracycline Susceptibility by Stalling Elongating Ribosomes.

Antimicrobial agents and chemotherapy

Liu B, Chen C.
PMID: 29784847
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.02356-17. Print 2018 Aug.

Even though elongation factor 4 (EF4) is the third most conserved protein in bacteria, its physiological functions remain largely unknown and its proposed molecular mechanisms are conflicting among previous studies. In the present study, we show that the growth...

Cite
Liu B, Chen C. Translation Elongation Factor 4 (LepA) Contributes to Tetracycline Susceptibility by Stalling Elongating Ribosomes. Antimicrob Agents Chemother. 2018;62(8)doi: 10.1128/AAC.02356-17.
Liu, B., & Chen, C. (2018). Translation Elongation Factor 4 (LepA) Contributes to Tetracycline Susceptibility by Stalling Elongating Ribosomes. Antimicrobial agents and chemotherapy, 62(8), . https://doi.org/10.1128/AAC.02356-17
Liu, Bin, and Chen, Chunlai. "Translation Elongation Factor 4 (LepA) Contributes to Tetracycline Susceptibility by Stalling Elongating Ribosomes." Antimicrobial agents and chemotherapy vol. 62,8 (2018). doi: https://doi.org/10.1128/AAC.02356-17
Liu B, Chen C. Translation Elongation Factor 4 (LepA) Contributes to Tetracycline Susceptibility by Stalling Elongating Ribosomes. Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.02356-17. Print 2018 Aug. PMID: 29784847; PMCID: PMC6105825.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 583 entries